Persons Reported to be living with HIV infection and with AIDS reported
Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 321 223 3 0 324 223 544 3 547
2001

326

234

 2 0 328 234 560 2 562
2002 407 262 4 0 411 262 669 4 673
                   

 

HIV Infection Cases  from areas with confidential HIV infection reporting
Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 44 375 4 379
2001 38 383 4 387
2002 23 407 4 411
         


 

Adult/Adolescent HIV infection and AIDS cases reported in the United States
Year Males Females
  HIV AIDS HIV AIDS
2000 30 21 14 1
2001 29 19 9 5
         

 

New Pediatric AIDS cases reported

Year
2000 0
2001 1
   

 

Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 547
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 544
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 3

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2002
  ID USA
Men 468 680,909
Women 61 146,298
Total 529 827,208

 

New AIDS Cases

New AIDS Cases, Reported through 2002 31
New Adult/Adolescent AIDS Cases, Reported in 2001 18
New AIDS Cases in Children <13, Reported through December 2001 1

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001
  ID USA
Men 14 31,901
Women 4 11,082
Total 18 42,983

 

Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 262
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 262
Estimated Number of Children Living with AIDS at the End of 2002 0
HIV Infection Cases Reported in 2002 23


 

Total Deaths Reported through 2000, due to AIDS = 269
HIV Reporting Requirements ?   Yes, Name Based.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions: Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?  Voluntary HIV testing; no specific law. State follows CDC guidelines; No specific law or language on testing for mothers and newborns.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration? NO, Has considered or is considering an 1115 Waiver to expand Medicaid eligibility to people with HIV.
Definitions: 1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 
Sterile Syringe Exchange Programs?  No
Notes: U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  Yes, No state-specific content requirements.
 
Minors' Right to Consent to HIV/STD Services?  Yes, Minor must be at least 14 years of age. State explicitly classifies HIV/AIDS as an STD or infectious disease, for which minors may consent to testing and treatment.

 

 
Total Ryan White Funding, FY2000   $1,096,465 FY2002  $1,661,432

 

CDC HIV Prevention Funding for States
 FY2001 n/a

 FY2003   $936,478

 

Total Federal and State Funding for ADAP, FY2000  $559,828

Definitions: ADAPs: AIDS Drug Assistance Programs (ADAPs), authorized under Title II of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, provide HIV-related prescription drugs to underinsured and uninsured individuals living with HIV/AIDS. Each state or territory administers its own ADAP.


 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation
 

Total ADAP Clients Served, June 2002  
  ID
#		 US
#
   81 80,035

 
ADAP Clients Served by Sex, June 2002  
  ID
#		 ID
%		 US
#		 US
%
  Male 67 83 62,034 78
  Female 14 17 16,702 21
  Total 81 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  ID
#		 ID
%		 US
#		 US
%
  White 65 80 29,426 37
  Black 1 1 26,245 33
  Hispanic 13 16 19,883 25
  Asian/Pacific Islander 0 0 795 1
  American Indian/Alaskan Native 2 3 795 1
  Other 0 0 795 1
  Total 81 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  ID
#		 ID
%		 US
#		 US
%
  <13 years old 1 1 795 1
  13-19 years old 0 0 0 1 0 1
  20-44 years old 52 64 50,105 63
  >44 years old 27 33 27,836 35
  Total 79 98 79,531 100

 
ADAP Clients Served by Income, June 2002  
  ID
#		 ID
%		 US
#		 US
%
  <100% FPL 41 51 38,175 48
  101-200% FPL 40 49 26,245 33
  201-300% FPL 0 0 8,748 11
  301-400% FPL 0 0 3,181 4
  >400% FPL 0 0 1,591 2
  Total 81 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  ID
#		 ID
%		 US
#		 US
%
  Medicaid 0 0 0 10
  Medicare 4 5 0 6
  Private 0 0 0 13

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  ID
$		 US
$
   794,940 878,610,754

 
National ADAP Budget by Source, FY 2002  
  ID
$		 ID
%		 US
$		 US
%
  ADAP Earmark 414,357 52 619,830,000 71
  Title II Base 118,407 15 28,886,192 3
  State 200,000 25 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 0 0 30,941,439 4
  ADAP Supplemental Grants 62,176 8 19,170,000 2
  Total 794,940 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  ID
$		 US
$
   89,706 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  ID
$		 ID
%		 US
$		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 51,653 58 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 14,335 16 7,940,575 12
  Protease Inhibitors 23,602 26 16,433,502 25
  Opportunistic Infections/Other 116 0 9,015,329 14
  Total 89,706 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  ID
#		 US
#
   247 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  ID
#		 ID
%		 US
#		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 143 58 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors 39 16 23,933 10
  Protease Inhibitors 53 21 33,813 15
  Opportunistic Infections/Other 12 5 87,746 38
  Total 247 100 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  ID
$		 US
$
   NA 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  ID
#		 US
#
  Nucleoside Reverse Transcriptase Inhibitors 9 NA
  Protease Inhibitors Covered 6 NA
  Non-nucleosides Covered 3 NA
  OI Prophylaxis Covered 14 NA
  Other Medications Covered 3 NA
  Total 35 NA

 
ADAP Emergency Cost Containment Measures, February 2003  
  ID
 		 US
 
  Has ADAP Emergency Cost Containment Measures in Place Yes 16 Yes
  Notes Capped enrollment; monthly per capita expenditure cap.